Posted by Michael Wonder on 22 Dec 2024
PHARMAC consulting on six medicines for New Zealanders
19 December 2024 - PHARMAC is asking for feedback on proposals to fund six medicines for cancer and antibiotic resistant infections from 1 April 2025.
The medicines are:
- Nivolumab (Opdivo) and ipilimumab (Yervoy) for kidney cancer as a first treatment option
- Sunitinib maleate for kidney cancer
- Axitinib (Inlyta) for kidney cancer when the cancer has spread and progressed after receiving other treatment
- Inotuzumab ozogamicin (Besponsa) for acute lymphoblastic leukaemia
- Crizotinib (Xalkori) for advanced non-small cell lung cancer with specific gene mutations
- Ceftazidime with avibactam (Zavicefta) for antibiotic resistant infections
